Bevezetés: A hereditaer nonpolyposus colorectalis carcinomára jellemző mutációk (HNPCC) autoszomális domináns öröklődésmenetet mutatnak. Leginkább vastagbéldaganatok kialakulásáért felelősek. Célkitűzés: A HNPCC-szindrómás betegek szűrésének és követésének fontosságát szeretnénk hangsúlyozni egy igazolt MMR-gén-mutációt hordozó betegünk jelenlegi és 10 évvel korábbi családfájának összehasonlításával. Betegek és módszer: Hazánkban előforduló, HNPCC-re gyanús családok kiszűrése érdekében alapos családi anamnézist veszünk fel. Amennyiben az immunhisztokémiai és mikroszatellitainstabilitás-vizsgálatok HNPCC-szindrómára utalnak, elvégezzük az MMR-gének szekvenálását. Eredmények: Betegünknél egy, a hMSH2-gén 6. exon két bázispárt érintő deletiója (c.969–970delTC) igazolódott. Tízéves utánkövetés során betegünknél és rokonainál újabb, a HNPCC-re jellemző tumorok jelentek meg. Következtetés: A veszélyeztetett családtagok követése során a szekunder prevenció a jól együttműködő betegeknél hatékony volt. Orv Hetil. 2017; 158(30): 1182–1187.
Schneikert J, Behrens J. The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 2007; 56: 417–425.
Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343: 78–85.
Peltomaki P, Vasen HF., The International Collaborative Group on HNPCC. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. Gastroenterology 1997; 113: 1146–1458.
Giardiello FM, Allen Jl, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gatroenterology 2014; 147: 502–526.
Lynch HT, Smyrk TC, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993; 104: 1535–1549.
Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes and historical perspectives. J Natl Cancer Inst. 1995; 87: 1114–1125.
Van de Wetering M, Sancho E, Verweij C, et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241–250.
Tamura G. Alterations of tumour suppressor and tumour-related genes in the development and progression of gastric cancer. World J Gastroenterol. 2006; 12: 192–198.
Weinberg RA. Maintenance of genomic integrity and the development of cancer. In: The biology of cancer. Garland Science, Taylor & Francis Group, LLC, New York and Abingdon, 2007; pp. 463–526.
Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res. 2002; 62: 2447–2454.
De la Chapelle A. Microsatellite instability. N Engl J Med. 2003; 349: 209–210.
Eisen JA. Mechanistic basis for microsatellite instability. In: Goldstein DB, Schlotterer C. (eds.) Microsatellites: Evolution and applications. Oxford University Press, Oxford, 1999; pp. 34–48.
Atkin NB. Microsatellite instability. Cytogenet Cell Genet. 2001; 92: 177–181.
Mori Y, Yin J, Rashid A, et al. Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability. Cancer Res. 2001; 61: 6046–6049.
Kovacs ME, Papp J, Szentirmay Z, et al. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat. 2009; 30: 197–203.
Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a ‘mutL’ homolog in hereditary colon cancer. Science 1994; 263: 1625–1629.
Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 2011; 12: 49–55.
Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med. 2009: 11: 3–14.
Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008; 10: 5783–5788.
Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71: 677–685.
Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 111: 1402.
Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014; 109: 1159–1179.
González-Aguilera JJ, Nejda N, Fernández FJ, et al. GeneticAL alterations and MSI status in primary, synchronous, and metachronous tumors in a family with hereditary nonpolyposis colorectal cancer (HNPCC). Am J Clin Oncol. 2003; 26: 386–391.
Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999; 116: 1453–1456.
Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998; 58: 3455–3460.
Tanyi M, Olasz J, Kámory E, et al. Difficulties in recognizing families with hereditary non-polyposis colorectal carcinoma: Presentation of 4 families with proven mutation. Eur J Surg Oncol. 2008; 34: 1322–1327.
Dove-Edwin I, Sasieni P, Adams J, et al. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 2005; 331: 1047.
Gerritzen LH, Hoogerbrugge N, Oei AL, et al. Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. Fam Cancer 2009; 8: 391–397.
Van der Post RS, Kiemeney LA, Ligtenberg MJ, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet. 2010; 47: 464–470.
Myrhøj T, Andersen MB, Bernstein I. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Fam Cancer 2008; 7: 3003–3007.